Cancer screening is the testing of people who do not necessarily have symptoms in order to identify certain cancers or precancerous changes at an earlier stage, when treatment may be more effective. Screening differs from diagnostic investigation because diagnostic tests are usually performed because symptoms, examination findings or another abnormal result have raised clinical suspicion. Screening programmes are designed for particular cancers and populations where evidence indicates that screening can provide a meaningful benefit. In the UK, established NHS programmes include screening for bowel, breast and cervical cancer, with eligibility determined by age, sex or other programme criteria.
A screening test does not necessarily detect cancer itself. Cervical screening, for example, primarily identifies high-risk human papillomavirus and, when appropriate, abnormal cervical cells that could develop into cancer. Bowel screening can detect blood in stool and may lead to further investigation such as colonoscopy. Breast screening uses mammography to identify abnormalities that may represent breast cancer. The distinction between screening and diagnosis is crucial because an abnormal screening result generally means that further assessment is required rather than proving that cancer is present.
Screening works best when the target disease has a detectable preclinical stage and when earlier intervention improves outcomes. A screening programme therefore needs more than an accurate test. There must be a defined target population, an acceptable balance between benefits and harms, appropriate follow-up for abnormal results and effective treatment for disease discovered through screening. Screening programmes also need to consider participation, accessibility, false-positive results, false-negative results, overdiagnosis and resource use. These factors explain why not every cancer has a recommended population-screening programme.
A false-positive screening result occurs when a test suggests possible cancer or precancerous disease when the person does not actually have the target condition. False positives can lead to additional imaging, biopsies, procedures, anxiety and other harms. A false-negative result occurs when a screening test fails to detect disease that is present. No screening test is perfectly sensitive or specific. The interpretation of an abnormal result must therefore be followed by appropriate diagnostic investigation, while a normal result reduces but does not eliminate the possibility of cancer.
Overdiagnosis is another important concept in cancer screening. It occurs when screening detects a cancer or cancerous change that would never have caused symptoms or harm during the person's lifetime. Because screening can identify very slow-growing or biologically indolent abnormalities, detecting more cancers does not necessarily mean that every detected cancer would have become clinically important. Overdiagnosis can lead to overtreatment, including surgery, radiotherapy or other interventions that would not have been necessary without screening. This is one reason screening policies are based on population-level evidence rather than simply on the ability of a test to find abnormalities.
Screening eligibility is deliberately limited in many programmes because the balance between benefit and harm changes with age and individual risk. For example, a test may have a favourable balance in a population at sufficient risk but produce too many false positives or unnecessary procedures in a much lower-risk population. People with symptoms should not wait for their next routine screening invitation; symptoms require diagnostic assessment through the appropriate healthcare pathway. Likewise, people with a strong family history or known genetic risk may require individualised surveillance that differs from standard population screening.
Cancer screening can reduce mortality from some cancers by shifting detection towards earlier stages or by preventing cancer through identification and treatment of precancerous disease. Cervical screening is particularly important because treating high-risk HPV-related precancerous abnormalities can prevent some cervical cancers from developing. However, screening is not prevention in every case, and it cannot guarantee that cancer will not occur. Some cancers develop between screening rounds, some are difficult to detect with available tests and some tumours are biologically aggressive despite early detection.
The modern concept of cancer screening developed alongside improvements in pathology, imaging and epidemiology, but contemporary programmes are governed by evidence about outcomes rather than by the simple availability of a test. The terms "screening", "surveillance", "case finding" and "diagnosis" are related but not interchangeable. Screening targets people without relevant symptoms in an organised or defined testing context, surveillance usually involves monitoring people known to have increased risk or a previous condition, and diagnosis investigates an abnormality or symptom. Understanding these distinctions is essential when interpreting screening invitations and results.
